Abstract Guidelines

CCICON 2026 Guwahati GUIDELINES FOR ORAL PRESENTATIONS AND E-POSTERS FOR CCICON 2026 Guwahati

Oral Presentation Guidelines

General Presentation Requirements

Presentation Duration: 7–8 minutes presentation followed by 2–3 minutes of Q&A.
Presentation Structure: Follow the standard scientific format: Introduction, Methods, Results, Discussion, and Conclusion.
Slide Format: Use a standard 16:9 widescreen layout with a dark blue, navy, or charcoal background for enhanced visibility.
Visual Content: Prioritize high-quality figures, graphs, flowcharts, and tables instead of large text blocks.
Font Requirements: Use professional fonts such as Arial, Helvetica, Calibri, or Times New Roman. Minimum font sizes:
- Headings: 48 pt or larger
- Body Text: 24 pt or larger
Presentation Delivery: Speak clearly, maintain eye contact, and emphasize key findings. Avoid reading directly from slides.
Disclosure: A Conflict of Interest (COI) disclosure slide is mandatory for all presenters.

Slide	Section	Description
1	Title & Presenter Information	• Study Title (Bold, 40pt+ font) • Your Name, Qualifications, and Institution (24pt font).
2	Conflict of Interest Disclosure	• Mandatory statement confirming any financial or institutional disclosures.
3	Introduction & Background	• Bullet 1: Current clinical context or problem statement. • Bullet 2: Knowledge gap in existing medical literature. • Bullet 3: Study Objective / Hypothesis.
4	Methodology	• Study design (e.g., Randomized Controlled Trial, Retrospective Cohort). • Patient population, inclusion/exclusion criteria, and sample size (n). • Sample size (n). • Primary and secondary endpoints.
5	Results – Participant Flow & Baseline Data	• CONSORT flowchart or basic demographic table.
6	Results – Primary Outcome	• High-resolution chart, graph, or survival curve.. • Minimal text; include statistical significance (p
7	Results – Secondary Outcomes	• Key secondary findings or subgroup analyses using visual tables.
8	Discussion	• Interpretation of major findings. • How results compare to prior landmark trials.
9	Limitations & Strengths	• 2–3 bullet points addressing study constraints and clinical strengths.
10	Conclusion & Clinical Implications	• Take-home message: How this changes clinical practice or future research.
11	Acknowledgements & Q&A	• Thank your team, mentors, and institutions. • "Questions?" text with your contact email.

E-Poster Presentations

Format
- Landscape or portrait slide in 16:9 format
- Save as PDF or PowerPoint file
Layout
- Use clear, readable headings
- Text should be visible from at least 2 feet away
- All images and charts should be at least 300 DPI
Word Count
- Keep content scannable
- Aim for 300–800 words maximum
- Treat it as a visual conversation starter, not a manuscript
Presentation
- Prepare a 3-minute mini-oral / elevator pitch
- Followed by 2 minutes of Q&A
General Rules
- Conflict of Interest:
  - Must be declared on the first slide or top corner of the poster
- File Naming:
  - Follow organizer format strictly (e.g., PresenterName_SessionNumber)
  - Submit before the deadline
- Backups:
  - Keep copies on USB drive
  - Keep a backup in email

Scientific Poster Column

Column 1: Introduction & Clinical Approach

1. Introduction

Clinical Background: Acute severe Condition Y remains a premier driver of critical care hospitalizations worldwide, carrying an estimated 30-day mortality rate of 15–20%.

The Knowledge Gap: Standard guideline-directed medical therapies often lack rapid onset, and the therapeutic window for implementing targeted secondary prevention remains poorly defined in existing clinical trials.

Study Objective: This randomized controlled trial sought to evaluate whether administering the novel agent Drug X within 6 hours of initial symptom onset improves 30-day all-cause mortality compared to standard therapy alone.

2. Methods

Study Framework: A phase III, multi-center, double-blind, randomized controlled clinical trial conducted across 4 tertiary academic medical institutions.
Patient Selection:
- Inclusion Criteria: Adult patients aged 18–75 years presenting with confirmed acute severe Condition Y within 6 hours of symptom onset.
- Exclusion Criteria: Prior history of end-stage renal disease (eGFR < 15 mL/min/1.73m²), active hemorrhage, or current pregnancy.
Intervention Protocols: Eligible participants were randomized in a strict 1:1 ratio to receive either an intravenous infusion of Drug X (n = 125) or a matching matching placebo injection (n = 125), alongside standard guideline-directed medical therapy.
Statistical Analysis: Primary analysis followed an intention-to-treat approach. Survival curves were constructed via the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HR) were calculated using a Cox proportional hazards regression model. Statistical significance was defined as a two-sided p-value < 0.05.

Column 2: Primary & Secondary Results

3. Results

Baseline Cohort Demographics: Baseline clinical characteristics, including age (mean: 58.4 years), sex distribution (46% female), and comorbidity burdens (e.g., hypertension, diabetes), were evenly balanced across the two study cohorts (all p > 0.05).

Primary Clinical Outcome

The primary endpoint of 30-day all-cause mortality was significantly lower in the Drug X cohort compared to the placebo cohort (8.0% vs. 17.6%).
This represents a 54% relative risk reduction in short-term mortality (Hazard Ratio [HR]: 0.46; 95% Confidence Interval [CI]: 0.23–0.89; p = 0.015).
o [Insert Visual Reference Here: Figure 1. Kaplan-Meier Survival Curves over 30 Days]

Secondary Outcomes

The median total length of hospital stay was significantly shorter in patients treated with Drug X compared to placebo (5.2 days vs. 8.5 days, p < 0.001).
Rehospitalization rates for secondary complications at 30 days trended lower in the intervention group but did not reach statistical significance (12.0% vs. 16.8%, p = 0.24).

Safety Profile

Incidence rates of severe adverse events, including major bleeding episodes (2.4% vs. 1.6%, p = 0.65) and acute kidney injury (4.0% vs. 3.2%, p = 0.72), did not significantly differ between the treatment arms.

Column 3: Clinical Discussions & Takeaways

4. Discussion

Core Interpretation: Early therapeutic intervention using Drug X substantially mitigates 30-day all-cause mortality without increasing the rate of severe treatment-limiting adverse clinical complications.

Literature Context: These findings validate earlier retrospective registry data while establishing a much higher tier of clinical evidence. The observed reduction in hospital length of stay suggests a substantial secondary benefit regarding institutional healthcare cost savings.

5. Strengths & Limitations

Key Study Strengths: Double-blinded design, high protocol compliance, and a multi-center setup that minimized localized provider biases.
Study Limitations: The study cohort was confined to a single geographic country, and the follow-up window was limited to 30 days, leaving long-term outcomes unassessed.

6. Conclusions & Clinical Implications

Main Takeaway

Early-initiated treatment using Drug X represents a safe, highly effective strategy to optimize survival outcomes in patients presenting with acute severe Condition Y.

Moving Forward: These findings support the integration of early Drug X protocols into standard emergency cardiac care pathways. Larger international trials are warranted to verify long-term efficacy across more diverse patient demographic profiles.

The authors declare that this research project was supported via an independent investigator-initiated grant from the Medical Research Foundation. The authors declare no additional financial conflicts of interest or institutional equities relative to this manuscript.

Smith J, et al. The Lancet Cardiovascular Health. 2023; 401(10382): 1125–1134.
Davis R, et al. Journal of Clinical Intervention. 2024; 15(3): 245–252.

Submit Abstract